In the rapidly evolving pharmaceutical landscape of Africa, many governments and businesses are actively working to localize drug production to ensure long-term medical sovereignty. While the intent behind local manufacturing is commendable—boosting jobs, lowering dependency, and strengthening supply chains—it is essential to evaluate the real costs associated with such efforts. For distributors, government procurement agencies,